Eswatini vs Senegal: Average cost of drugs for extensively drug-resistant tuberculosis
Eswatini
2,726 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Eswatini rank
22nd
Senegal rank
20th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Eswatini
- Senegal
How they compare
Senegal currently reports 3,428 constant 2022 US$ against 2,726 constant 2022 US$ in Eswatini, a difference of 702 constant 2022 US$.
That makes Senegal's figure about 1.3 times Eswatini's.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Eswatini ahead.
Eswatini ranks 22nd and Senegal ranks 20th of 56 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 27,711 constant 2022 US$ | 5,308 constant 2022 US$ | 22,403 constant 2022 US$ | Eswatini |
| 2020s | 8,293 constant 2022 US$ | 2,890 constant 2022 US$ | 5,402 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Eswatini or Senegal?
- Senegal, at 3,428 constant 2022 US$ against 2,726 constant 2022 US$ in Eswatini as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Eswatini and Senegal?
- 702 constant 2022 US$, with Senegal ahead.
- How many years of comparable data are there for Eswatini and Senegal?
- 5 years are reported by both, from 2018 to 2024.
- How do Eswatini and Senegal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Eswatini ranks 22nd and Senegal ranks 20th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.